Comparison of Clinical and Imaging Parameters between Baseline, Day 9, and Day 28 After Commencing AB in both Hormone-Sensitive (C1) and Castrate-Resistant (C2) Disease States
| Variable | Baseline (C1) | Day 9 (C1) | Day 28 (C1) | Baseline (C2) | Day 9 (C2) | Day 28 (C2) |
| Number of men | 8/8 | 7/8 | 8/8 | 7/7 | 6/7 | 7/7 |
| PSA (ng/mL) | 80 (15.7–148) | 17 (5–46) | 6 (1.3–15) | 9.2 (6.4–49) | 9.2 (2.5–32) | 13.3 (2.3–32) |
| Testosterone (nmol/L) | 11.6 (7.6–20) | 2 (0.8–14.6) | 0.6 (0.3–.9) | 0.3 (0.3–0.6) | 0.3 (0.3–0.35 | 0.3 (0.3–0.4) |
| PSMA SUVmax tumor | 23 (8.7–32.5) | 17 (5–46) | 14 (0.8–22) | 20.2 (11–52) | 42 (15–88) | 27 (17–55) |
| PSMA SUVmean tumor | 6.7 (3.4–8.4) | 5.7 (2.9–7.6) | 5.4 (0.5–6.6) | 6 (4.4–7.7) | 7.7 (4.7–12.2) | 6.1 (5–9.2) |
| PSMA tumor volume (mL) | 61 (11.5–254) | 42 (7–273) | 22 (0.5–204) | 60 (36–293) | 163 (36–972) | 149 (22–389) |
| PSMA salivary gland SUVmax | 14.3 (13–16.3) | 14.1 (10 −18) | 15.4 (14.3–18) | 14.7 (9.3–18) | 14.8 (11.9–18) | 12.8 (12.4–16) |
Data in parentheses are IQRs.